The Conversation
Edition:
Available editions
Africa
Job Board
Become an author
Sign up as a reader
Sign in
The Conversation
Academic rigour, journalistic flair
Arts + Culture
Business + Economy
Education
Environment + Energy
Health + Medicine
Politics + Society
Science + Technology
In French
Drug-resistant TB: a new study offers new hope
March 21, 2019 2.57pm SAST
Authors
Andrew Nunn
Senior scientist, MRC Clinical Trials Unit at UCL, UCL
I.D. Rusen
Adjunct Professor, Dalla Lana School of Public Health , University of Toronto
Disclosure statement
Andrew Nunn receives funding from the Medical Research Council (UK) and for conduct of the STREAM trial from USAID.
I.D. Rusen receives funding through a USAID Cooperative Agreement for TB Research that supported this research. Rusen is a senior advisor at the International Union Against Tuberculosis and Lung Disease (The Union) in Paris and Senior Vice President for Division of Research and Development, Vital Strategies, New York.
Partners
University College London
University of Toronto
University College London provides funding as a founding partner of The Conversation UK.
University of Toronto provides funding as a founding partner of The Conversation CA.
University of Toronto provides funding as a member of The Conversation CA-FR.
The Conversation is funded by the National Research Foundation, eight universities, including the Cape Peninsula University of Technology, Rhodes University, Stellenbosch University and the Universities of Cape Town, Johannesburg, Kwa-Zulu Natal, Pretoria, and South Africa. It is hosted by the Universities of the Witwatersrand and Western Cape, the African Population and Health Research Centre and the Nigerian Academy of Science. The Bill & Melinda Gates Foundation is a Strategic Partner. more
Republish this article
Republish
Republish our articles for free, online or in print, under Creative Commons licence.
New research holds promise of a shorter treatment course for people with drugresistant- TB. Daniel Irungu/EPA
Email
Twitter2
Facebook
LinkedIn
Print
Tuberculosis (TB) is the leading cause of death in the world from a single infectious disease, causing more deaths than HIV/AIDS. In 2017, 10 million people developed TB disease globally and an estimated 1.6 million died.
One of the biggest blocks to beating the epidemic is the growing resistance to drugs that have previously cured TB.
The World Health Organisation (WHO) has declared drug-resistant TB a global health crisis. Worldwide in 2017, an estimated 558,000 people developed TB that was resistant to the most effective first-line drug – rifampicin (RR-TB). Of these, 82% had multidrug-resistant TB.
But treating drug-resistant TB is still hopelessly inefficient. The 20-month to 24-month regimen used in many countries to treat people is costly and has significant side effects. In addition, the length of the regimen makes it hard for patients to adhere to, as well as for health systems to sustain. Globally, the regimen has an average treatment success rate of little more than 50% in real-world treatment settings, although there is considerable variation from country to country.
As a result researchers around the world have been urgently exploring shorter, more effective, and safer treatments for patients who have drug-resistant TB.
One of these efforts has begun to bear fruit. Results from Stage 1 of a clinical trial have recently been published. The news is encouraging. The trial provides evidence that a shorter treatment regimen – of nine to 11 months – is as effective for the treatment of multidrug-resistant TB as the longer, 20-month treatment recommended by the WHO in 2011.
The STREAM trial presents robust evidence for the effectiveness and safety of the nine to 11-month regimen when compared to the much longer 20-month regimen. The results are as good and the fact that the regimen is shorter should make it much more acceptable to patients. It is also likely to result in cost saving to both patients and health services.
The trial
The STREAM trial (Standardised Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) is the world’s first multi-country randomised phase III clinical trial to test the efficacy, safety and economic impact of shortened MDR-TB treatment regimens. The randomised nature of the trial means that patients were assigned to the long or short regimen in such a way as so as to avoid bias. Treatment allocation is determined by chance not by the choice of a physician.
Phase III trials are designed to assess the effectiveness and safety of a new intervention in practice.
Stage 1 of the trial was designed to assess whether a nine to 11-month treatment regimen that demonstrated promising cure rates during a pilot programme in Bangladesh, is as effective as the longer regimen when assessed in other settings under rigorous control trial conditions. Seven sites in Vietnam, Mongolia, South Africa, and Ethiopia participated.
The results from Stage 1 show that the shorter regimen is as good as the 20-month regimen.
Nearly 80% of patients in the trial showed a favourable outcome after two and a half years of follow-up from entry into the trial. The percentage was 79.8% in the 20-month regimen. In the nine to 11-month regimen the percentage was 78.8%.
Results in participants with HIV, although not as good as in those who were HIV-negative, were very similar in the short and long regimen.
The findings on side-effects were also interesting. There were very similar rates of severe side-effects during treatment and follow-up between the two regimens. But there were differences in the types of side-effects. The most common side-effects were cardiac conduction disorders, which increase the risk of serious and potentially fatal arrhythmias, in the nine to 11-month regimen. In the 20-month regimen the most common side effects were metabolic disorders, particularly hypokalemia.
A health economics data analysis is ongoing and will assess potential cost savings to patients and health systems when the nine to 11-month regimen is compared to the 20-month regimen.
Conclusions
The final results from the trial are encouraging because they show that the nine to 11-month treatment regimen is comparable in efficacy and safety to the 20-month regimen. This supports the use of a shorter regimen for patients with rifampicin-resistant TB.
The nine to 11-month regimen presents substantial advantages. It reduces treatment times, may improve patient retention under programmatic conditions, and reduces the number of pills patients have to take.
However, the required ECG monitoring is an important consideration.
In its latest guidelines issued last year the WHO again highlighted the need to continue to look for regimens that are not only shorter, but are also less toxic for the patient. The STREAM Stage 1 results suggest that some progress is being made.
STREAM Stage 2 is currently evaluating an all-oral regimen that is potentially as effective and more tolerable than the injectable-containing regimens currently used some countries. This, too, would be another major step forward in the battle against MDR-TB.
Public health
Tuberculosis
TB
Ethiopia
Mongolia
Vietnam
Epidemic
Bangladesh
South Africa
World TB Day
drug-resistant-TB
Global Perspectives
Tweet
Share
Get newsletter
You might also like
TB doesn’t only attack the lungs – other organs are also vulnerable
South Africa kicks the can down the road on captive predator breeding
Safari tourism may make elephants more aggressive – but it’s still the best tool for conservation
Major battles have been won against TB. But the war isn’t over
Sign in to comment
0 Comments
There are no comments on this article yet.
Have your say, post a comment on this article.
Most popular on The Conversation
Tropical cyclone Idai: The storm that knew no boundaries
Why it’s significant that the UK has returned the locks of hair of an Ethiopian king
Responses to Zimbabwe highlight gulf between the region and the west
What a failed Johannesburg project tells us about mega cities in Africa
Why Malawi is failing to protect people from floods and what needs to be done
Free to reproduce, free to exploit: South Africa’s copyright amendment bill
Universities must stop relying on software to deal with plagiarism
Botswana joins list of African countries reviewing gay rights
We asked Senegalese migrants why they leave home. Here’s what they told us
Developing countries would benefit from improved tax collection. What can help
Expert Database
Find experts with knowledge in:*
Want to write?
Write an article and join a growing community of more than 81,400 academics and researchers from 2,775 institutions.
Register now
The Conversation
Community
Community standards
Republishing guidelines
Research and Expert Database
Analytics
Job Board
Our feeds
Company
Who we are
Our charter
Our team
Partners and funders
Resource for media
Contact us
Stay informed and subscribe to our free daily newsletter and get the latest analysis and commentary directly in your inbox.
Email address
Follow us on social media
Privacy policy Terms and conditions Corrections
Copyright © 2010–2019, The Conversation Africa, Inc.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment